Get the Stockscreener App
3.5887
12.14%
-0.4613
Sonnet Biotherapeutics Holdings Inc stock is traded at $3.5887, with a volume of 166.26K.
It is down -12.14% in the last 24 hours and up +217.71% over the past month.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
See More
Previous Close:
$4.05
Open:
$3.92
24h Volume:
166.26K
Relative Volume:
0.05
Market Cap:
$11.33M
Revenue:
$129.20K
Net Income/Loss:
$-7.44M
P/E Ratio:
-0.3207
EPS:
-11.19
Net Cash Flow:
$-8.62M
1W Performance:
-30.90%
1M Performance:
+217.71%
6M Performance:
+110.56%
1Y Performance:
-48.06%
1-Day Range:
$3.5501
$3.92
1-Week Range:
$3.5501
$5.05
52-Week Range:
$1.08
$19.30
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile
Name
Sonnet Biotherapeutics Holdings Inc
Sector
Industry
Phone
609-375-2227
Address
100 OVERLOOK CENTER, PRINCETON, NJ
Compare SONN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SONN
Sonnet Biotherapeutics Holdings Inc
|
3.58 | 24.99M | 129.20K | -7.44M | -8.62M | -11.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.64 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
553.33 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.35 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
593.62 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.15 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Latest News
What is the risk reward ratio of investing in Sonnet BioTherapeutics Holdings Inc. stockCapitalize on trading strategies that deliver - jammulinksnews.com
Analyzing net buyer seller activity in Sonnet BioTherapeutics Holdings Inc.Insider Strategy for High Conviction Picks - Newser
Why is Sonnet BioTherapeutics Holdings Inc. stock attracting strong analyst attentionAchieve breakthrough profits with smart strategies - jammulinksnews.com
What institutional investors are buying Sonnet BioTherapeutics Holdings Inc. stockCapitalize on momentum-driven investment opportunities - jammulinksnews.com
What is the dividend policy of Sonnet BioTherapeutics Holdings Inc. stockUnlock exclusive stock market insights - jammulinksnews.com
Is Sonnet BioTherapeutics Holdings Inc. stock overvalued or undervaluedMaximize returns with strategic stock selection - jammulinksnews.com
How strong is Sonnet BioTherapeutics Holdings Inc. company’s balance sheetUncover the best stocks for explosive growth - jammulinksnews.com
Why Sonnet BioTherapeutics Holdings Inc. stock attracts strong analyst attentionHigh Return Potential - Newser
How Interest Rate Changes Impact Sonnet BioTherapeutics Holdings Inc. Stock PerformanceFree Access to Community - Newser
Top Risks to Consider Before Buying Sonnet BioTherapeutics Holdings Inc. StockFree Deep Market Trend Analysis - Newser
What drives Sonnet BioTherapeutics Holdings Inc. stock priceSuperior profit margins - PrintWeekIndia
Sonnet BioTherapeutics Holdings Inc. Stock Analysis and ForecastFree Stock Chart Pattern Guide - PrintWeekIndia
Is Sonnet BioTherapeutics Holdings Inc. a good long term investmentFree Capital Efficiency Planning - PrintWeekIndia
How Sonnet BioTherapeutics Holdings Inc. stock performs during market volatilityFree Market Analysis Group - Newser
What analysts say about Sonnet BioTherapeutics Holdings Inc. stockConsistently superior profits - jammulinksnews.com
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. - Yahoo.co
Halper Sadeh investigates Sonnet BioTherapeutics, First Community Corp, Monogram Technologies mergers. - AInvest
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SONN, FCCO, MGRM on Behalf of Shareholders - GlobeNewswire Inc.
Biotech Minnow Sonnet Takes A Hard Turn Into Crypto - Finimize
Sonnet BioTherapeutics Secures Funding to Meet Nasdaq Requirements - TipRanks
Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors - ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Sonnet BioTherapeutics Bets Big on HYPE Token as Charts Signal 161% Rally Potential - CoinChapter
Sonnet BioTherapeutics’ New Strategy with $888 Million Worth of Crypto Reserves! - Pintu
Sonnet BioTherapeutics Launches $583 Million Crypto Treasury With HYPE Token - AInvest
Hyperliquid Strategies Inc. plan for $583M treasury boosts HYPE price - Cointelegraph
Sonnet BioTherapeutics Announces $888M Combination With Rorschach For HYPE Treasury - Tekedia
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.73%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):